NHS-Galleri Trial Participants Complete Third and Final Appointments

The Northern Cancer Alliance is proud to support the NHS-Galleri trial. The NHS-Galleri trial is looking into the use of a blood test to see if it can help the NHS to detect cancer early when used alongside existing cancer screening.

140,000 people have volunteered to take part in the trial across England. From July 2024 participants will have completed their last of three trial appointments. Although participants will not be invited to any more appointments, the trial does not end here. This is because health information will continue to be collected from the NHS to support the research. To find out what happens next in the trial, please visit nhs-galleri.org. Please note, the trial is not accepting new participants.

Please remember that you should continue to attend any cancer screening visits you are invited to and visit your GP if you experience any symptoms which are new or unusual for you.

The study is being carried out in partnership with NHS England and GRAIL Bio UK Ltd, and is being run by The Cancer Research UK & King’s College London Cancer Prevention Trials Unit, a team of cancer researchers and trial managers at King’s College London.

GRAIL, Inc is a company in the United States that developed the test. They have also set up an affiliate in the UK, GRAIL Bio UK Ltd (GRAIL), who are the main funder and organiser of this trial.

For more information, visit nhs-galleri.org